The Power List is our chance to put the pharmaceutical and drug development industry’s inspirational thought leaders, opinion shapers and unsung heroes in the spotlight. We’re relying on you to ensure that the breadth of perspectives is as wide as possible!

Solutions in... Drug Development

There are no drugs currently approved to treat metastatic triple negative breast cancer. And for the majority of cancers with treatments available, there remains a significant number of patients for whom the drugs do not work – and we have a limited understanding of why this is the case.

Background

Although many standard chemotherapy drugs have been on the market for a long time, they may only work in around 60 or 70 percent of patients. For certain kinds of cancer, such as bladder cancer or malignant melanoma, the available drugs only work 20 to 30 percent of the time, and in some cancers it’s as low as eight percent of patients. The reasons behind this are unclear, but it highlights why we need more personalized and precise treatments for patients. Immunotherapy drugs are one such approach, but when you take the breaks off the immune system, it can go into hyperdrive and begin killing healthy tissue in addition to cancer cells.

Read the full article now

Log in or register to read this article in full and gain access to
The Medicine Maker’s entire content archive. It’s FREE and always will be!

Or Login as a Guest or via Social Media

About the Author

James Strachan

Over the course of my Biomedical Sciences degree it dawned on me that my goal of becoming a scientist didn’t quite mesh with my lack of affinity for lab work. Thinking on my decision to pursue biology rather than English at age 15 – despite an aptitude for the latter – I realized that science writing was a way to combine what I loved with what I was good at.

From there I set out to gather as much freelancing experience as I could, spending 2 years developing scientific content for International Innovation, before completing an MSc in Science Communication. After gaining invaluable experience in supporting the communications efforts of CERN and IN-PART, I joined Texere – where I am focused on producing consistently engaging, cutting-edge and innovative content for our specialist audiences around the world.